View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 08, 2019
Document and Entity Information
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Entity Registrant Name	EYENOVIA, INC.
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Trading Symbol	EYEN
Entity Common Stock, Shares Outstanding		17,100,726
Entity Central Index Key	0001682639
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 9,239,609	$ 19,728,200
Prepaid expenses and other current assets	569,561	132,756
Total Current Assets	9,809,170	19,860,956
Property and equipment, net	31,632	36,738
Deferred offering costs	77,376	0
Security deposit	117,800	117,800
Total Assets	10,035,978	20,015,494
Current Liabilities:
Accounts payable	1,802,386	1,509,524
Accrued compensation	437,700	912,104
Accrued expenses and other current liabilities	133,146	677,213
Total Current Liabilities	2,373,232	3,098,841
Deferred rent	44,817	41,584
Total Liabilities	2,418,049	3,140,425
Commitments and contingencies (Note 6)
Stockholders' Equity:
Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2019 and as of December 31, 2018	0	0
Common stock, $0.0001 par value, 90,000,000 shares authorized; 12,053,963 and 11,468,996 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	1,205	1,147
Additional paid-in capital	55,396,914	53,388,216
Accumulated deficit	(47,780,190)	(36,514,294)
Total Stockholders' Equity	7,617,929	16,875,069
Total Liabilities and Stockholders' Equity	$ 10,035,978	$ 20,015,494

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Condensed Balance Sheets
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	6,000,000	6,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	12,053,963	11,468,996
Common Stock, Shares, Outstanding	12,053,963	11,468,996

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Condensed Statements of Operations - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating Expenses:
Research and development	$ 3,568,022	$ 2,412,164	$ 7,576,918	$ 4,506,259
General and administrative	1,809,106	908,806	3,751,869	2,246,455
Total Operating Expenses	5,377,128	3,320,970	11,328,787	6,752,714
Loss From Operations	(5,377,128)	(3,320,970)	(11,328,787)	(6,752,714)
Other Income:
Interest income	43,616	1,907	62,891	4,044
Net Loss	$ (5,333,512)	$ (3,319,063)	$ (11,265,896)	$ (6,748,670)
Net Loss Per Share
- Basic and Diluted	$ (0.44)	$ (0.33)	$ (0.94)	$ (0.77)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	12,034,450	9,998,646	11,975,035	8,807,864

Condensed Statement of Changes in Stockholders' Equity - USD ($)

Series A Convertible Preferred Stock [Member]

Series A-2 Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Total

Balance at Dec. 31, 2017

$ 293

$ 79

$ 92

$ 257

$ 24,351,138

$ (19,261,186)

$ 5,090,673

Balance (in shares) at Dec. 31, 2017

2,932,431

788,827

918,983

2,566,530

Conversion of convertible preferred stock into common stock upon completion of initial public offering

$ (293)

$ (79)

$ (92)

$ 464

Conversion of convertible preferred stock into common stock upon completion of initial public offering (in shares)

(2,932,431)

(788,827)

(918,983)

4,640,241

Issuance of common stock in initial public offering

^[1]

$ 0

$ 273

24,547,530

24,547,803

Issuance of common stock in initial public offering (in shares)

^[1]

2,730,000

Stock-based compensation

$ 0

650,576

Net loss

(3,429,607)

Balance at Mar. 31, 2018

$ 0

$ 994

49,549,244

(22,690,793)

26,859,445

Balance (in shares) at Mar. 31, 2018

9,936,771

Balance at Dec. 31, 2017

$ 293

$ 79

$ 92

$ 257

24,351,138

(19,261,186)

5,090,673

Balance (in shares) at Dec. 31, 2017

2,932,431

788,827

918,983

2,566,530

Net loss

(6,748,670)

Balance at Jun. 30, 2018

$ 0

$ 1,000

49,550,750

(26,009,856)

23,541,894

Balance (in shares) at Jun. 30, 2018

9,998,646

Balance at Mar. 31, 2018

$ 0

$ 994

49,549,244

(22,690,793)

26,859,445

Balance (in shares) at Mar. 31, 2018

9,936,771

Conversion of convertible preferred stock into common stock upon completion of initial public offering

$ 0

$ 6

(6)

Conversion of convertible preferred stock into common stock upon completion of initial public offering (in shares)

61,875

Stock-based compensation

$ 0

1,512

Net loss

(3,319,063)

Balance at Jun. 30, 2018

$ 0

$ 1,000

49,550,750

(26,009,856)

23,541,894

Balance (in shares) at Jun. 30, 2018

9,998,646

Balance at Dec. 31, 2018

$ 1,147

53,388,216

(36,514,294)

16,875,069

Balance (in shares) at Dec. 31, 2018

11,468,996

Exercise of stock options on a cashless basis

$ 24

(24)

Exercise of stock options on a cashless basis (in shares)

236,466

Exercise of stock options

$ 31

483,857

483,888

Exercise of stock options (in shares)

313,686

Stock-based compensation

$ 0

1,032,960

Net loss

(5,932,384)

Balance at Mar. 31, 2019

$ 1,202

54,905,009

(42,446,678)

12,459,533

Balance (in shares) at Mar. 31, 2019

12,019,148

Balance at Dec. 31, 2018

$ 1,147

53,388,216

(36,514,294)

16,875,069

Balance (in shares) at Dec. 31, 2018

11,468,996

Net loss

(11,265,896)

Balance at Jun. 30, 2019

$ 1,205

55,396,914

(47,780,190)

7,617,929

Balance (in shares) at Jun. 30, 2019

12,053,963

Balance at Mar. 31, 2019

$ 1,202

54,905,009

(42,446,678)

12,459,533

Balance (in shares) at Mar. 31, 2019

12,019,148

Exercise of stock options

$ 3

67,886

67,889

Exercise of stock options (in shares)

34,815

Stock-based compensation

$ 0

424,019

Net loss

(5,333,512)

Balance at Jun. 30, 2019

$ 1,205

$ 55,396,914

$ (47,780,190)

$ 7,617,929

Balance (in shares) at Jun. 30, 2019

12,053,963

[1]	Includes gross proceeds of $27,300,000, less total issuance costs of $2,752,197.

Condensed Statement of Changes in Stockholders' Equity (Parenthetical)	6 Months Ended
	Jun. 30, 2019 USD ($)
Condensed Statement of Changes in Stockholders' Equity
Proceeds Of Stock Issued During Period Gross	$ 27,300,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 2,752,197

Condensed Statements of Cash Flows - USD ($)

6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Cash Flows From Operating Activities:

Net loss

$ (11,265,896)

$ (6,748,670)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

5,106

11,483

Stock-based compensation

1,456,979

652,088

Changes in operating assets and liabilities:

Prepaid expenses and other current assets

(436,805)

(206,308)

Accounts payable

216,186

476,622

Accrued compensation

(474,404)

Accrued expenses and other current liabilities

(544,767)

383,482

Deferred rent

3,233

Net Cash Used In Operating Activities

(11,040,368)

(5,431,303)

Cash Flows From Financing Activities:

Proceeds from exercise of stock options

551,777

Proceeds from sale of common stock in initial public offering

^[1]

25,089,000

Payment of initial public offering issuance costs

(345,497)

Net Cash Provided By Financing Activities

551,777

24,743,503

Net (Decrease) Increase in Cash and Cash Equivalents

(10,488,591)

19,312,200

Cash and Cash Equivalents - Beginning of Period

19,728,200

5,249,511

Cash and Cash Equivalents - End of Period

9,239,609

24,561,711

Supplemental Disclosure of Non-Cash Financing Activities:

Exercise of stock options on a cashless basis

Deferred offering costs included in accounts payable

77,376

Conversion of convertible preferred stock into common stock

464

Reversal of previously accrued initial public offering issuance costs

(133,000)

Reduction of additional paid-in capital for initial public offering issuance costs that were previously paid

$ 0

$ (195,700)

[1]	Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds.

Condensed Statements of Cash Flows (Parenthetical)	6 Months Ended
Condensed Statements of Cash Flows (Parenthetical)	Jun. 30, 2019 USD ($)
Condensed Statements of Cash Flows
Proceeds Of Stock Issued During Period Gross	$ 27,300,000
Payments of Debt Issuance Costs	$ 2,211,000

Business Organization, Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Business Organization, Nature of Operations and Basis of Presentation
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation Eyenovia. Inc. (“Eyenovia” or the “Company”) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the OptejetTM. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, Optejet has demonstrated up to a 75% reduction in ocular drug and preservative exposure, with successful topical delivery that is consistent with the efficacy of traditional eyedrop administration. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration (the “FDA”). Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are not classified by the FDA as medical devices or drug-device combination products. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the operating results for the full year ending December 31, 2019 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2018 and for the year then ended, which were filed with the Securities and Exchange Commission (“SEC”) on Form 10‑K on March 27, 2019.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Since the date of the Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

Liquidity and Financial Condition

The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. Subsequent to June 30, 2019, the Company closed on a public offering of its common stock that provided approximately $13.0 million of net proceeds. See Note 10 – Subsequent Events for additional details.

The Company believes its current cash on hand, including the proceeds received from its subsequent public offering, is sufficient to meet its operating and capital requirements for at least the next twelve months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.

The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of June 30, 2019 and December 31, 2018, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $8,989,609 and $19,478,200, respectively.

Deferred Offering Costs

Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company’s public or private offerings are capitalized as non-current assets on the balance sheet. Upon the closing of an offering, the deferred offering costs are offset against the offering proceeds. As of June 30, 2019 and December 31, 2018, there were deferred offering costs for legal fees associated with the public offering of the Company’s common stock subsequent to June 30, 2019 in the amount of $77,376 and $0, respectively.

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.

The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:


	June 30,
	2019	2018
Options	1,563,366	1,860,084
Warrants	—	61,875
Restricted Stock Units	20,165	—
Total potentially dilutive shares	1,583,531	1,921,959

Recently Adopted Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective basis unless it is impracticable to apply, in which case the Company would be required to apply the amendments prospectively as of the earliest date practicable. This standard was adopted on January 1, 2019 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718)” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, “Equity — Equity-Based Payments to Nonemployees.” The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of ASU No. 2014-09, (Topic 606), “Revenue from Contracts with Customers.” This standard was adopted on January 1, 2019 and did not have a material impact on the Company’s financial position, results of operations or cash flows.

Prepaid Expenses and Other Current Assets

6 Months Ended

Jun. 30, 2019

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

Note 3 – Prepaid Expenses and Other Current Assets

As of June 30, 2019 and December 31, 2018, prepaid expenses and other current assets consisted of the following:


	June 30,			December 31,
	2019		2018
	(unaudited)
Prepaid insurance expenses	$	274,685	$	39,465
Payroll tax credit receivable		101,049		—
Prepaid research & development expenses		84,058		—
Prepaid rent and security deposit		30,837		75,729
Prepaid patent expenses		27,832		10,562
Prepaid filing expenses		27,500		—
Prepaid conference expenses		23,600		7,000
Total prepaid expenses and other current assets	$	569,561	$	132,756

Accrued Compensation

6 Months Ended

Jun. 30, 2019

Accrued Compensation

Accrued Compensation

Note 4 – Accrued Compensation

As of June 30, 2019 and December 31, 2018, accrued compensation consisted of the following:


	June 30,		December 31,
	2019		2018
	(unaudited)
Accrued bonus expenses	$	332,771	$	694,490
Accrued payroll expenses		104,929		217,614
Total accrued compensation	$	437,700	$	912,104

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2019

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

Note 5 – Accrued Expenses and Other Current Liabilities

As of June 30, 2019 and December 31, 2018, accrued expenses and other current liabilities consisted of the following:


	June 30,		December 31,
	2019		2018
	(unaudited)
Accrued research and development expenses	$	46,927	$	375,204
Credit card payable		29,885		9,466
Accrued professional services		26,747		111,728
Accrued travel and enterntainment expenses		14,388		—
Accrued franchise tax		12,875
Accrued legal expenses		—		168,650
Other		2,324		12,165
Total accrued expenses and other current liabilities	$	133,146	$	677,213

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2019
Commitments and Contingencies
Commitments and Contingencies	Note 6 – Commitments and Contingencies Employment Agreements Effective February 15, 2019, the Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, its Vice President, Clinical Operations, Luke Clauson, its Vice President, Research and Development and Manufacturing, and Michael Rowe, its Vice President, Marketing. Each of the employment agreements provides that if the executive’s employment is terminated by the Company without “Cause” or the executive suffers an “Involuntarily Termination” (each as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier. Each of the employment agreements also provides that if within 12 months following any “Corporate Transaction” (as defined in the employment agreements) of the Company, if the executive’s employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier. Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2019
Related Party Transactions
Related Party Transactions	Note 7 – Related Party Transactions Consulting Agreements A company in which a member of the Company’s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company incurred expenses of $50,634 and $34,884 for the three months ended June 30, 2019 and 2018, respectively, and $98,835 and $92,460 for the six months ended June 30, 2019 and 2018, respectively, related to the agreement which was included within general and administrative expenses on the condensed statements of operations. Lease Agreements The Company paid $3,000 and $4,000 per month as of July 2016 and January 2018, respectively, to a company controlled by a member of its Board of Directors for office space in New York, NY for its Chief Executive Officer. The Company left the space on August 31, 2018. During the three months ended June 30, 2019 and 2018, the Company recorded rent expense of $0 and $9,000, respectively, and $0 and $18,000 for the six months ended June 30, 2019 and 2018, respectively, related to the office space which was included within general and administrative expenses on the condensed statements of operations. The Company’s Vice President of Research and Development and Manufacturing (“VP of R&D”) owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit was $3,895. On September 15, 2018, the Company amended the lease agreement to extend it until September 14, 2020 and increase the monthly base rent and security deposit to $4,012. The Company made $40,000 of leasehold improvements related to this lease which are included on the balance sheet. The Company’s rent expense amounted to $12,036 and $11,685 for the three months ended June 30, 2019 and 2018, respectively, and $24,072 and $23,370, respectively, for the six months ended June 30, 2019 and 2018, respectively. Research and Development Activities The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the three and six months ended June 30, 2019, the Company recognized research and development expense of $210,419 and $530,560, respectively, related to services provided by such vendor. During the three and six months ended June 30, 2018, the Company recognized research and development expense of $196,432 and $428,443, respectively, related to services provided by such vendor. The Company had a liability of $211,160 and $100,667 to the vendor as of June 30, 2019 and December 31, 2018, respectively. The Company recognized $46,050 and $94,100 of compensation expense related to the VP of R&D’s salary during the three and six months ended June 30, 2019, respectively. The Company recognized $41,250 and $82,500 of compensation expense during the three and six months ended June 30, 2018, respectively. License Agreement During 2015, the Company entered into a license agreement with Senju Pharmaceuticals Co., Ltd. (“Senju”) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a microdose product candidate in Asia, such that no royalties had been earned. Senju is owned by the family of a former member of the Company’s Board of Directors and both beneficially own greater than 5% of the Company’s common stock.

Stockholders' Equity

6 Months Ended

Jun. 30, 2019

Stockholders' Equity

Stockholders' Equity

Note 8 – Stockholders’ Equity

Stock Options

During the six months ended June 30, 2019, the Company granted ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan. The 11,000 shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock options have an exercise price of $2.74 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date value of $27,500, which the Company expects to recognize over the vesting period.

On January 2, 2019, stock options to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for aggregate proceeds of $483,888.

On February 6, 2019, stock options to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.

On February 13, 2019, the Board of Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr. Ianchulev on July 24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company recognized $609,322 of stock-based compensation expense during the six months ended June 30, 2019, which represents the remaining unamortized grant date fair value of the award.

On May 14, 2019, stock options to purchase 34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:


	For the Three Months Ended		For the Six Months Ended
	June 30,		June 30,
	2019	2018	2019	2018
Expected term (years)	n/a	5.82 - 10.0	5.85	5.82 - 10.0
Risk free interest rate	n/a	2.69% - 2.83%	2.53%	2.69% - 2.83%
Expected volatility	n/a	140%	139%	140%
Expected dividends	n/a	0.00%	0.00%	0.00%

The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company does not yet have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

There were no stock options granted during the three months ended June 30, 2019. The weighted average estimated grant date fair value of the stock options granted for the six months ended June 30, 2019 was approximately $2.74 per share. The weighted average estimated grant date fair value of the stock options granted for the three and six months ended June 30, 2018 was approximately $8.72 per share.

A summary of the option activity during the six months ended June 30, 2019 is presented below:


				Weighted
		Weighted		Average
		Average		Remaining	Aggregate
	Number of	Exercise		Life	Intrinsic
	Options	Price		In Years	Value
Outstanding January 1, 2019	2,220,868	$	3.01
Granted	11,000		2.74
Exercised	(668,502)		1.42
Forfeited	—		—
Outstanding June 30, 2019	1,563,366	$	3.69	8.0	$	2,459,670

Exercisable June 30, 2019	921,648	$	3.07	7.6	$	1,764,949

The following table presents information related to stock options as of June 30, 2019:


Options Outstanding			Options Exercisable
			Weighted
		Outstanding	Average	Exercisable
Exercise		Number of	Remaining Life	Number of
Price		Options	In Years	Options
$	1.24	260,000	5.7	260,000
$	1.95	700,281	8.0	412,212
$	2.74	11,000	—	—
$	4.00	2,000	—	—
$	5.10	6,000	—	—
$	5.19	16,500	—	—
$	5.25	26,668	7.3	17,916
$	6.20	311,499	9.1	146,535
$	6.30	60,000	9.0	18,333
$	8.72	169,418	8.8	66,652
		1,563,366	7.6	921,648

Stock-Based Compensation Expense

The Company records stock-based compensation expense related to stock options and restricted stock units. During the three months ended June 30, 2019 and 2018, the Company recorded expense of $424,019 ($206,834 of which was included within research and development expenses and $217,185 was included within general and administrative expenses on the condensed statements of operations) and $1,512 ($11,369 of which was included within research and development expenses and $(9,857) was included within general and administrative expenses on the condensed statements of operations which includes a credit associated with the mark-to-market of non-employee options), respectively. During six three months ended June 30, 2019 and 2018, the Company recorded expense of $1,456,979 ($900,917 of which was included within research and development expenses and $556,062 was included within general and administrative expenses on the condensed statements of operations) and $652,088 ($316,290 of which was included within research and development expenses and $335,798 was included within general and administrative expenses on the condensed statements of operations), respectively. As of June 30, 2019, there was $2,301,431 of unrecognized stock-based compensation expense which will be recognized over a weighted average period of 1.7 years.

Employee Benefit Plans	6 Months Ended
Employee Benefit Plans	Jun. 30, 2019
Employee Benefit Plans
Employee Benefit Plans	Note 9 – Employee Benefit Plans 401(k) Plan In April 2019, the Company adopted the Eyenovia 401(k) Plan (the “Plan”), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2019, the Company’s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the three and six months ended June 30, 2019, the Company recorded expense of $16,043 associated with its matching contributions.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2019
Subsequent Events
Subsequent Events	Note 10 – Subsequent Events Public Offering On July 15, 2019, the Company closed an underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company’s common stock at the same price, which was exercised in full on July 16, 2019. Including the over-allotment shares, the Company issued a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million and net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Summary of Significant Accounting Policies

Liquidity and Financial Condition

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.

Deferred Offering Costs

Stock-Based Compensation

Net Loss Per Common Share

The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:


	June 30,
	2019	2018
Options	1,563,366	1,860,084
Warrants	—	61,875
Restricted Stock Units	20,165	—
Total potentially dilutive shares	1,583,531	1,921,959

Recently Adopted Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Summary of Significant Accounting Policies

Schedule of anti-dilutive weighted average diluted common shares

The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:


	June 30,
	2019	2018
Options	1,563,366	1,860,084
Warrants	—	61,875
Restricted Stock Units	20,165	—
Total potentially dilutive shares	1,583,531	1,921,959

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2019

Prepaid Expenses and Other Current Assets

Schedule of prepaid expenses and other current assets

As of June 30, 2019 and December 31, 2018, prepaid expenses and other current assets consisted of the following:


	June 30,			December 31,
	2019		2018
	(unaudited)
Prepaid insurance expenses	$	274,685	$	39,465
Payroll tax credit receivable		101,049		—
Prepaid research & development expenses		84,058		—
Prepaid rent and security deposit		30,837		75,729
Prepaid patent expenses		27,832		10,562
Prepaid filing expenses		27,500		—
Prepaid conference expenses		23,600		7,000
Total prepaid expenses and other current assets	$	569,561	$	132,756

Accrued Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Accrued Compensation

Schedule of accrued compensation

As of June 30, 2019 and December 31, 2018, accrued compensation consisted of the following:


	June 30,		December 31,
	2019		2018
	(unaudited)
Accrued bonus expenses	$	332,771	$	694,490
Accrued payroll expenses		104,929		217,614
Total accrued compensation	$	437,700	$	912,104

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2019

Accrued Expenses and Other Current Liabilities

Schedule of accrued expenses and other current liabilities

As of June 30, 2019 and December 31, 2018, accrued expenses and other current liabilities consisted of the following:


	June 30,		December 31,
	2019		2018
	(unaudited)
Accrued research and development expenses	$	46,927	$	375,204
Credit card payable		29,885		9,466
Accrued professional services		26,747		111,728
Accrued travel and enterntainment expenses		14,388		—
Accrued franchise tax		12,875
Accrued legal expenses		—		168,650
Other		2,324		12,165
Total accrued expenses and other current liabilities	$	133,146	$	677,213

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2019

Stockholders' Equity

Schedule of Black-Scholes option pricing model to stock options granted

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:


	For the Three Months Ended		For the Six Months Ended
	June 30,		June 30,
	2019	2018	2019	2018
Expected term (years)	n/a	5.82 - 10.0	5.85	5.82 - 10.0
Risk free interest rate	n/a	2.69% - 2.83%	2.53%	2.69% - 2.83%
Expected volatility	n/a	140%	139%	140%
Expected dividends	n/a	0.00%	0.00%	0.00%

Schedule of the stock option activity

A summary of the option activity during the six months ended June 30, 2019 is presented below:


				Weighted
		Weighted		Average
		Average		Remaining	Aggregate
	Number of	Exercise		Life	Intrinsic
	Options	Price		In Years	Value
Outstanding January 1, 2019	2,220,868	$	3.01
Granted	11,000		2.74
Exercised	(668,502)		1.42
Forfeited	—		—
Outstanding June 30, 2019	1,563,366	$	3.69	8.0	$	2,459,670

Exercisable June 30, 2019	921,648	$	3.07	7.6	$	1,764,949

Schedule of information related to stock options

The following table presents information related to stock options as of June 30, 2019:


Options Outstanding			Options Exercisable
			Weighted
		Outstanding	Average	Exercisable
Exercise		Number of	Remaining Life	Number of
Price		Options	In Years	Options
$	1.24	260,000	5.7	260,000
$	1.95	700,281	8.0	412,212
$	2.74	11,000	—	—
$	4.00	2,000	—	—
$	5.10	6,000	—	—
$	5.19	16,500	—	—
$	5.25	26,668	7.3	17,916
$	6.20	311,499	9.1	146,535
$	6.30	60,000	9.0	18,333
$	8.72	169,418	8.8	66,652
		1,563,366	7.6	921,648

Business Organization, Nature of Operations and Basis of Presentation - (Details)	6 Months Ended
	Jun. 30, 2019
Business Organization, Nature of Operations and Basis of Presentation
Percentage reduction in preservative	75.00%

Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,583,531	1,921,959
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,165	0
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	61,875
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,563,366	1,860,084

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Summary of Significant Accounting Policies
Cash, Uninsured Amount	$ 8,989,609	$ 19,478,200
Proceeds from Issuance Initial Public Offering	13,000,000
Deferred Costs	$ 77,376	$ 0

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Prepaid Expenses and Other Current Assets
Prepaid insurance expenses	$ 274,685	$ 39,465
Payroll tax credit receivable	101,049	0
Prepaid research & development expenses	84,058	0
Prepaid rent and security deposit	30,837	75,729
Prepaid patent expenses	27,832	10,562
Prepaid filling expenses	27,500	0
Prepaid conference expenses	23,600	7,000
Total prepaid expenses and other current assets	$ 569,561	$ 132,756

Accrued Compensation (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued Compensation
Accrued bonus expenses	$ 332,771	$ 694,490
Accrued payroll expenses	104,929	217,614
Total accrued compensation	$ 437,700	$ 912,104

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued Expenses and Other Current Liabilities
Accrued research and development expenses	$ 46,927	$ 375,204
Credit card payable	29,885	9,466
Accrued professional services	26,747	111,728
Accrued travel and entertainment expenses	14,388	0
Accrued franchise tax	12,875	0
Accrued legal expenses	0	168,650
Other	2,324	12,165
Total accrued expenses and other current liabilities	$ 133,146	$ 677,213

Commitments and Contingencies (Details)	6 Months Ended
Commitments and Contingencies (Details)	Jun. 30, 2019 USD ($)
Commitments and Contingencies
Severance Costs	$ 419,000
Supplemental Unemployment Benefits, Salary Continuation	$ 1,677,000

Related Party Transactions (Details)		1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
Related Party Transactions (Details)	Jul. 06, 2017 USD ($)	Jan. 31, 2018 USD ($)	Sep. 15, 2016 USD ($) ft²	Jul. 31, 2016 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2015	Dec. 31, 2018 USD ($)	Sep. 15, 2018 USD ($)
Operating Leases, Rent Expense					$ 0	$ 9,000	$ 0	$ 18,000
Security Deposit					117,800		117,800			$ 117,800
Minority Interest Ownership Percentage In Company									5.00%
Payments for Rent		$ 4,000		$ 3,000
Vice President of Research and Development [Member]
Cost Of Services Engineering Services					210,419	196,432	530,560	428,443
Net Rentable Area \| ft²			953
Lease, Monthly Base Rent			$ 3,895
Operating Lease, Expense					12,036	11,685	24,072	23,370
Security Deposit			$ 3,895								$ 4,012
Officers' Compensation					46,050	41,250	94,100	82,500
Leasehold Improvements, Gross					40,000		40,000
Senju Pharmaceutical Co [Member]
Royalty Percentage									(5.00%)
Research and Development Expense [Member] \| Vice President of Research and Development [Member]
Due to Related Parties					211,160		211,160			$ 100,667
Cura Partners [Member] \| Consulting Agreement [Member]
Consulting Fee	$ 9,567
Consulting agreement payment, Per hour	$ 250
Cura Partners [Member] \| General and Administrative Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party					$ 50,634	$ 34,884	$ 98,835	$ 92,460

Stockholders' Equity (Details)	3 Months Ended	6 Months Ended
Stockholders' Equity (Details)	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Expected term (years)		5 years 10 months 6 days	0 years
Risk free interest rate		2.53%	0.00%
Expected volatility	140.00%	139.00%	140.00%
Expected dividends	0.00%	0.00%	0.00%
Minimum [Member]
Expected term (years)	5 years 9 months 26 days		5 years 9 months 26 days
Risk free interest rate	2.69%		2.69%
Maximum [Member]
Expected term (years)	10 years		10 years
Risk free interest rate	2.83%		2.83%

Stockholders' Equity - Summary of option activity (Details) - USD ($)			3 Months Ended	6 Months Ended
	May 14, 2019	Feb. 06, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Number of Options Exercised \| Shares	(34,815)	(320,001)
Weighted Average Exercise Price, Granted \| $ / Shares				$ 2.74
Weighted Average Exercise Price, Exercised	$ 1.95		$ 8.72		$ 8.72
Weighted Average Exercise Price, Exercisable \| $ / Shares		$ 1.24
Equity Option [Member]
Number of Options Outstanding \| Shares				2,220,868
Number of Options Granted \| Shares				11,000
Number of Options Exercised \| Shares				(668,502)
Number of Options Forfeited \| Shares				0
Number of Options Outstanding \| Shares				1,563,366
Number of Options Exercisable \| Shares				921,648
Weighted Average Exercise Price, Outstanding \| $ / Shares				$ 3.01
Weighted Average Exercise Price, Granted \| $ / Shares				2.74
Weighted Average Exercise Price, Exercised				1.42
Weighted Average Exercise Price, Forfeited \| $ / Shares				0.00
Weighted Average Exercise Price, Outstanding \| $ / Shares				3.69
Weighted Average Exercise Price, Exercisable \| $ / Shares				$ 3.07
Weighted Average Remaining Life In Years, Outstanding				8 years
Weighted Average Remaining Life In Years, Exercisable				7 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding \| $				$ 2,459,670
Aggregate Intrinsic Value, Exercisable				$ 1,764,949

Stockholders' Equity - Summary of information related to stock options (Details)	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Options Outstanding, Outstanding Number of Options	1,563,366
Options Exercisable, Weighted Average Remaining Life In Years	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	921,648
Exercise Price 1.24 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 1.24
Options Outstanding, Outstanding Number of Options	260,000
Options Exercisable, Weighted Average Remaining Life In Years	5 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	260,000
Exercise Price 1.95 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 1.95
Options Outstanding, Outstanding Number of Options	700,281
Options Exercisable, Weighted Average Remaining Life In Years	8 years
Options Exercisable, Exercisable Number of Options	412,212
Exercise Price 2.74 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 2.74
Options Outstanding, Outstanding Number of Options	11,000
Options Exercisable, Exercisable Number of Options	0
Exercise Price 4.00 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 4.00
Options Outstanding, Outstanding Number of Options	2,000
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.10 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.10
Options Outstanding, Outstanding Number of Options	6,000
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.19 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.19
Options Outstanding, Outstanding Number of Options	16,500
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.25 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.25
Options Outstanding, Outstanding Number of Options	26,668
Options Exercisable, Weighted Average Remaining Life In Years	7 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	17,916
Exercise Price 6.20 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 6.20
Options Outstanding, Outstanding Number of Options	311,499
Options Exercisable, Weighted Average Remaining Life In Years	9 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	146,535
Exercise Price 6.30 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 6.30
Options Outstanding, Outstanding Number of Options	60,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years
Options Exercisable, Exercisable Number of Options	18,333
Exercise Price 8.72 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 8.72
Options Outstanding, Outstanding Number of Options	169,418
Options Exercisable, Weighted Average Remaining Life In Years	8 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	66,652

Stockholders' Equity - Additional Information (Details) - USD ($)					3 Months Ended			6 Months Ended
	May 14, 2019	Feb. 13, 2019	Feb. 06, 2019	Jan. 02, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock Issued During Period, Shares, New Issues			236,466
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options					$ 2,301,431			$ 2,301,431
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								3 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 2.74
Share-based Compensation					424,019		$ 1,512	$ 1,456,979	$ 652,088
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost								609,322
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	34,815		320,001
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 1.95						$ 8.72		$ 8.72
Proceeds from Stock Options Exercised	$ 67,889			$ 483,888				551,777	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price			$ 1.24
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number		124,210
Research and Development Expense [Member]
Share-based Compensation					206,834		$ 11,369	900,917	316,290
General and Administrative Expense [Member]
Share-based Compensation					$ 217,185		$ 9,857	$ 556,062	$ 335,798
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				133,686	34,815	313,686
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 1.95
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				180,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 1.24
Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage								0.33%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								11,000
Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								24 months
Employees Consultants and Directors Under the 2018 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								11,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 2.74
Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Grant Date Fair Value								$ 27,500

Employee Benefit Plans (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
Employee Benefit Plans (Details) - USD ($)	Apr. 30, 2019	Jun. 30, 2019	Jun. 30, 2019
Employee Benefit Plans
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	4.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount		$ 16,043	$ 16,043

Subsequent Events (Details) - USD ($)					1 Months Ended	6 Months Ended
Subsequent Events (Details) - USD ($)	Jul. 15, 2019	May 14, 2019	Feb. 06, 2019	Jan. 02, 2019	Jul. 16, 2019	Jun. 30, 2019	Jun. 30, 2018
Stock Issued During Period, Shares, New Issues			236,466
Proceeds from Stock Options Exercised		$ 67,889		$ 483,888		$ 551,777	$ 0
Subsequent Event [Member]
Net Proceeds From Issuance Of Common Stock	$ 13,000,000
Gross Proceeds Of Stock Value Issued During Period	$ 14,000,000
Subsequent Event [Member] \| Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues	5,046,763				658,273
Subsequent Event [Member] \| IPO [Member]
Stock Issued During Period, Shares, New Issues	4,388,490
Shares Issued, Price Per Share	$ 2.78